...
anro-img

Alto Neuroscience, Inc., Common Stock

ANRO

NYQ

$4

+$0.11

(2.83%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$104.91M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
188.64K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.56 L
$24 H
$4

About Alto Neuroscience, Inc., Common Stock

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameANROSectorS&P500
1-Week Return6.67%-0.94%-2.6%
1-Month Return-9.5%-5.08%-1.08%
3-Month Return-69.9%-10.62%3.45%
6-Month Return-61.76%-6.18%8.57%
1-Year Return-75%1.98%24.3%

Financials

Sep '21Sep '22Sep '23
Total Revenue210.00K--[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Cost of Revenue145.00K342.00K373.00K[{"date":"2021-09-30","value":38.87,"profit":true},{"date":"2022-09-30","value":91.69,"profit":true},{"date":"2023-09-30","value":100,"profit":true}]
Gross Profit65.00K(342.00K)(373.00K)[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-526.15,"profit":false},{"date":"2023-09-30","value":-573.85,"profit":false}]
Gross Margin30.95%--[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Operating Expenses12.12M28.85M37.81M[{"date":"2021-09-30","value":32.06,"profit":true},{"date":"2022-09-30","value":76.3,"profit":true},{"date":"2023-09-30","value":100,"profit":true}]
Operating Income(12.06M)(29.19M)(37.81M)[{"date":"2021-09-30","value":-1205600000,"profit":false},{"date":"2022-09-30","value":-2919200000,"profit":false},{"date":"2023-09-30","value":-3780900000,"profit":false}]
Total Non-Operating Income/Expense2.87M1.60M2.48M[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":55.59,"profit":true},{"date":"2023-09-30","value":86.49,"profit":true}]
Pre-Tax Income(9.19M)(27.71M)(36.30M)[{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false}]
Income Taxes---[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Income After Taxes---[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Income From Continuous Operations(9.19M)(27.71M)(36.30M)[{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false}]
Income From Discontinued Operations---[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Net Income(9.19M)(27.71M)(36.30M)[{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false}]
EPS (Diluted)---[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANRO
Cash Ratio 12.96
Current Ratio 13.09

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANRO
ROA (LTM) -32.36%
ROE (LTM) -56.72%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANRO
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANRO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.64
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Alto Neuroscience, Inc. share price today?

Alto Neuroscience, Inc. (ANRO) share price today is $4

Can Indians buy Alto Neuroscience, Inc. shares?

Yes, Indians can buy shares of Alto Neuroscience, Inc. (ANRO) on Vested. To buy Alto Neuroscience, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alto Neuroscience, Inc. be purchased?

Yes, you can purchase fractional shares of Alto Neuroscience, Inc. (ANRO) via the Vested app. You can start investing in Alto Neuroscience, Inc. (ANRO) with a minimum investment of $1.

How to invest in Alto Neuroscience, Inc. shares from India?

You can invest in shares of Alto Neuroscience, Inc. (ANRO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANRO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alto Neuroscience, Inc. shares
What is Alto Neuroscience, Inc. 52-week high and low stock price?

The 52-week high price of Alto Neuroscience, Inc. (ANRO) is $24. The 52-week low price of Alto Neuroscience, Inc. (ANRO) is $3.56.

What is Alto Neuroscience, Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Alto Neuroscience, Inc. (ANRO) is

What is Alto Neuroscience, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alto Neuroscience, Inc. (ANRO) is 0.64

What is Alto Neuroscience, Inc. dividend yield?

The dividend yield of Alto Neuroscience, Inc. (ANRO) is 0.00%

What is the Market Cap of Alto Neuroscience, Inc.?

The market capitalization of Alto Neuroscience, Inc. (ANRO) is $104.91M

What is Alto Neuroscience, Inc.’s stock symbol?

The stock symbol (or ticker) of Alto Neuroscience, Inc. is ANRO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top